Do you work on parasites and reside in an LMIC? Consider applying for a 2025 MPM LMIC award. The deadline is March 3rd, 2025—details on the website.
https://t.co/fsZx5aOho8
Our lab's recent work, an Editor's Pick in JBC, was featured on Science Daily: Toxoplasma gondii parasite uses unconventional method to make proteins for evasion of drug treatment.
📢 In one month, @veupathdb is hosting a FREE virtual workshop! Dec 11-13, 2024, 3 hours per day. Short lectures & hands-on exercises will help you make the best use of our vast resources to enhance your research. Details/registration: https://t.co/RhDVwnIdMw
🌟 Exciting news! Join Virtual Symposium on Apicomplexan Parasites (Apicomplexa-2025), happening Jan 22-23, 2025 (ET), covering latest research findings (mostly unpublished) in the field of #Plasmodium, #Toxoplasma, and #Cryptosporidium. 📲Learn more: https://t.co/n0SrdnZWOW #rt
Congratulations to Mike Holmes, whose latest paper was featured on the cover of mBio.
(Reduced expression of mRNA cap-binding protein eIF4E1 in Toxoplasma gondii bradyzoites. Red, eIF4E1; green: bradyzoite cyst wall marker; blue, DAPI)
Excited to present the latest preprint from the lab, showing that Toxoplasma gondii parasites use cap-independent translation to convert into its latent cyst form! Here’s why this is cool... (1/n)
Our latest study, led by Mike Holmes, in mBio today: "mRNA cap-binding protein eIF4E1 is a novel regulator of Toxoplasma gondii latency"
We found an unexpected role for eIF4E1 that further links control of protein synthesis to microbial latency
https://t.co/nHapZ6l7H4
Please RT:
Applications are open at https://t.co/w8YNKaqCVk for the 2024 Biology of Parasitism course @MBLBoP@MBLScience with new deadline: January 3rd !!
Come join us for an amazing summer of learning and camaraderie, exciting lectures, lab practicals and fun excursions.
New study in Nature Communications featuring work by Drs. Michael Holmes & Bill Sullivan (@wjsullivan)
"A transcriptional network required for bradyzoite development in Toxoplasma gondii is dispensable for recrudescent disease"
https://t.co/20Y42y30QB